DUBLIN, Dec 20, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Congestive Heart Failure (CHF) Treatment Devices Market" report to their offering.
The congestive heart failure (CHF) treatment devices market is expected to reach USD 32.0 billion by 2024. The rising burden of CVDs is one of the prime factors responsible for lucrative growth of this vertical. Sedentary lifestyles, mental stress, and junk food consumption tendencies are the key factors responsible for development of CVDs.
Favorable reimbursement policies, such as the U.S. Medicare system, are observed to be a prime growth factor for this industry. Companies now provide new product platforms, which have reimbursement coverage that benefit the patient. The reimbursement can be availed for devices, such as Ventricular Assist Devices (VADs), Implantable Cardiovascular Defibrillators (ICDs), and pacemakers, which are used to treat CHF.
The industry participants are more focused on developing high-utility products, which can deliver personalized care. These advancements are improving the accuracy and provide additional capabilities to enhance the workflow and reduce the incidence of errors.
Asia-Pacific is anticipated to grow at a lucrative CAGR during the forecast period due to the increasing demand for these products. Furthermore, the rapidly improving healthcare infrastructure in the countries, such as India and Japan, also contribute toward the growth of this region.
- Jarvik Heart Inc.
- ReliantHeart, Inc.
- Biotronik SE & Co., KG
- Berlin Heart GmbH
- St. Jude Medical, Inc.
- Boston Scientific Corporation
- Teleflex, Inc.
Key Topics Covered:
1 Research Methodology
2 Executive Summary
3 Market Snapshot
4 Market Variables, Trends & Scope
5 Market Categorization : Product Estimates & Trend Analysis
6 Market Categorization: Regional Estimates & Trend Analysis, by Product
7 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/csqntx/congestive_heart
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/congestive-heart-failure-chf-treatment-devices-market-to-reach-32-billion-by-2024---rising-burden-of-cvds-is-a-key-factor---research-and-markets-300382097.html
SOURCE Research and Markets